Castle Biosciences (CSTL) announced its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders. DecisionDx-Melanoma is a 31-gene expression profile test that provides comprehensive, personalized results designed to improve risk-aligned management decisions for patients with stage I-III cutaneous melanoma. “We are excited by this milestone, which we believe is a testament to our shared desire with the melanoma healthcare community to improve the lives of patients,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “With every DecisionDx-Melanoma test, we aim to enable clinicians to make more informed, more precise treatment decisions that can improve patient outcomes.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle supports educational programs, initiatives for esophageal cancer
- Castle Biosciences announces publication of papers on DecisionDx-Melanoma test
- Castle Biosciences price target lowered to $30 from $37 at Guggenheim
- Castle Biosciences management to meet with Stephens
- Castle Biosciences: Strong Buy Rating Driven by TissueCypher’s Promising Growth and Strategic Market Positioning
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue